Abstract：
OBJECTIVE: The aim of this study was to determine the single and combined antidiabetic activity and side effects of the retinoid X receptor agonist bexarotene and the thioredoxin-interacting protein inhibitor and peroxisome proliferator-activated receptor γ and AMP-activated protein kinase activator icariin.
METHODS: The rats were grouped as healthy (control), diabetes, diabetes + bexarotene (20 mg/kg), diabetes + icariin (60 mg/kg), diabetes + bexarotene (10 mg/kg) + icariin (30 mg/kg) low-dose combination and diabetes + bexarotene (20 mg/kg) + icariin (60 mg/kg) high-dose combination groups.
RESULTS: Icariin treatment led to a significant reduction in glucose levels compared with the diabetes control group, a remarkable outcome observed 45 days after the initial application. HbA1c levels of the icariin and low-dose combination treatment groups were significantly lower than in the diabetes group. Notably, icariin treatment also significantly elevated HOMA-β levels, which is indicative of improved β-cell function. Icariin significantly decreased glucose levels at 30 and 120 min in the oral glucose tolerance test. Moreover, it ameliorated hepatocyte degeneration, hepatic cord dissociation, congestion, mononuclear cell infiltration in the liver, and degeneration in the pancreas.
CONCLUSIONS: Icariin treatment exhibited robust antidiabetic effects with fewer side effects than other treatment options in this study. In future studies, long-term and varying doses of icariin will contribute to the development of novel antidiabetic drugs.
METHODS: The rats were grouped as healthy (control), diabetes, diabetes + bexarotene (20 mg/kg), diabetes + icariin (60 mg/kg), diabetes + bexarotene (10 mg/kg) + icariin (30 mg/kg) low-dose combination and diabetes + bexarotene (20 mg/kg) + icariin (60 mg/kg) high-dose combination groups.
RESULTS: Icariin treatment led to a significant reduction in glucose levels compared with the diabetes control group, a remarkable outcome observed 45 days after the initial application. HbA1c levels of the icariin and low-dose combination treatment groups were significantly lower than in the diabetes group. Notably, icariin treatment also significantly elevated HOMA-β levels, which is indicative of improved β-cell function. Icariin significantly decreased glucose levels at 30 and 120 min in the oral glucose tolerance test. Moreover, it ameliorated hepatocyte degeneration, hepatic cord dissociation, congestion, mononuclear cell infiltration in the liver, and degeneration in the pancreas.
CONCLUSIONS: Icariin treatment exhibited robust antidiabetic effects with fewer side effects than other treatment options in this study. In future studies, long-term and varying doses of icariin will contribute to the development of novel antidiabetic drugs.
摘要：
目的：本研究的目的是确定类维生素X受体激动剂贝沙罗汀和硫氧还蛋白相互作用蛋白抑制剂以及过氧化物酶体增殖物激活受体γ和AMP激活蛋白激酶激活剂淫羊藿苷的单一和联合抗糖尿病活性和副作用。
方法：将大鼠分组为健康（对照组），糖尿病,糖尿病+贝沙罗汀（20mg/kg），糖尿病+淫羊藿苷（60毫克/千克），糖尿病+贝沙罗汀（10mg/kg）+淫羊藿苷（30mg/kg）低剂量组合和糖尿病+贝沙罗汀（20mg/kg）+淫羊藿苷（60mg/kg）高剂量组合组。
结果：与糖尿病对照组相比，淫羊藿苷治疗导致血糖水平显着降低，首次应用后45天观察到显着的结果。淫羊藿苷和低剂量联合治疗组的HbA1c水平明显低于糖尿病组。值得注意的是,淫羊藿苷治疗也显著升高HOMA-β水平，这表明β细胞功能改善。在口服葡萄糖耐量试验中，淫羊藿苷在30和120分钟时可显着降低葡萄糖水平。此外，它改善了肝细胞变性，肝脐带解离，拥塞，肝脏中的单核细胞浸润,胰腺退化。
结论：淫羊藿苷治疗显示出强大的抗糖尿病作用，副作用比其他治疗方案少。在未来的研究中,长期和不同剂量的淫羊藿苷将有助于新型抗糖尿病药物的开发。
方法：将大鼠分组为健康（对照组），糖尿病,糖尿病+贝沙罗汀（20mg/kg），糖尿病+淫羊藿苷（60毫克/千克），糖尿病+贝沙罗汀（10mg/kg）+淫羊藿苷（30mg/kg）低剂量组合和糖尿病+贝沙罗汀（20mg/kg）+淫羊藿苷（60mg/kg）高剂量组合组。
结果：与糖尿病对照组相比，淫羊藿苷治疗导致血糖水平显着降低，首次应用后45天观察到显着的结果。淫羊藿苷和低剂量联合治疗组的HbA1c水平明显低于糖尿病组。值得注意的是,淫羊藿苷治疗也显著升高HOMA-β水平，这表明β细胞功能改善。在口服葡萄糖耐量试验中，淫羊藿苷在30和120分钟时可显着降低葡萄糖水平。此外，它改善了肝细胞变性，肝脐带解离，拥塞，肝脏中的单核细胞浸润,胰腺退化。
结论：淫羊藿苷治疗显示出强大的抗糖尿病作用，副作用比其他治疗方案少。在未来的研究中,长期和不同剂量的淫羊藿苷将有助于新型抗糖尿病药物的开发。
